Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease
Keywords: اتموکسیدین; Parkinson's disease; Noradrenaline; Atomoxetine; LPS; Rat;